218 related articles for article (PubMed ID: 15461871)
1. Infliximab monotherapy for refractory psoriasis: preliminary results.
Cassano N; Loconsole F; Amoruso A; Coviello C; Filieri M; Filotico R; Del Vecchio S; Vena GA
Int J Immunopathol Pharmacol; 2004; 17(3):373-80. PubMed ID: 15461871
[TBL] [Abstract][Full Text] [Related]
2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
3. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for psoriasis and psoriatic arthritis.
Antoni C; Manger B
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S122-5. PubMed ID: 12463461
[TBL] [Abstract][Full Text] [Related]
5. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.
Feletar M; Brockbank JE; Schentag CT; Lapp V; Gladman DD
Ann Rheum Dis; 2004 Feb; 63(2):156-61. PubMed ID: 14722204
[TBL] [Abstract][Full Text] [Related]
7. Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
[TBL] [Abstract][Full Text] [Related]
8. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
9. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
10. Cytokine profiles during infliximab monotherapy in psoriatic arthritis.
Mastroianni A; Minutilli E; Mussi A; Bordignon V; Trento E; D'Agosto G; Cordiali-Fei P; Berardesca E
Br J Dermatol; 2005 Sep; 153(3):531-6. PubMed ID: 16120138
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
12. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.
Schopf RE; Aust H; Knop J
J Am Acad Dermatol; 2002 Jun; 46(6):886-91. PubMed ID: 12063486
[TBL] [Abstract][Full Text] [Related]
13. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
[TBL] [Abstract][Full Text] [Related]
14. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
15. Treatment of severe psoriasis with infliximab: report of two cases.
Peternel S; Prpić-Massari L; Guina T; Novak S; Brajac I; Kastelan M
Acta Dermatovenerol Croat; 2009; 17(3):204-6. PubMed ID: 19818221
[TBL] [Abstract][Full Text] [Related]
16. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.
Ogilvie AL; Antoni C; Dechant C; Manger B; Kalden JR; Schuler G; Lüftl M
Br J Dermatol; 2001 Mar; 144(3):587-9. PubMed ID: 11260020
[TBL] [Abstract][Full Text] [Related]
17. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
[TBL] [Abstract][Full Text] [Related]
18. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
Kavanaugh A; Krueger GG; Beutler A; Guzzo C; Zhou B; Dooley LT; Mease PJ; Gladman DD; de Vlam K; Geusens PP; Birbara C; Halter DG; Antoni C;
Ann Rheum Dis; 2007 Apr; 66(4):498-505. PubMed ID: 17114188
[TBL] [Abstract][Full Text] [Related]
19. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
Antoni CE; Kavanaugh A; van der Heijde D; Beutler A; Keenan G; Zhou B; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman DD; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen JS
J Rheumatol; 2008 May; 35(5):869-76. PubMed ID: 18381786
[TBL] [Abstract][Full Text] [Related]
20. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review.
Kamili QU; Miner A; Hapa A; Menter A
J Drugs Dermatol; 2011 May; 10(5):539-44. PubMed ID: 21533302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
